Baseline demographic and clinical characteristics
| . | N . | % . |
|---|---|---|
| Total number of treated patients | 19 | |
| Median age (range) | 63 (31, 79) | |
| Gender | ||
| Male | 12 | 63.2 |
| Female | 7 | 36.8 |
| Disease | ||
| AML | 17 | 89.5 |
| De novo (% of AML) | 8 | 47.1 |
| AML-MRC (% of AML) | 7 | 36.8 |
| AML with antecedent MPN (% of AML) | 2 | 10.5 |
| MDS-EB | 2 | 10.5 |
| Cytogenetic risk | ||
| AML | ||
| Intermediate (% of AML) | 14 | 82.4 |
| Normal (% of AML) | 11 | 64.7 |
| Adverse (% of AML) | 3 | 17.6 |
| MDS | ||
| Intermediate (% of MDS) | 2 | 100 |
| IDH2 mutation subtype | ||
| R140Q | 10 | 52.6 |
| R172K | 7 | 36.8 |
| R172G | 1 | 5.26 |
| Not available | 1 | 5.26 |
| Number of lines of treatment before HCT | ||
| 1 (newly diagnosed) | 15 | 78.9 |
| 2 (R/R) | 4 | 21.1 |
| Enasidenib before HCT | 10 | 52.6 |
| Conditioning | ||
| Myeloablative | 4 | 21.1 |
| Reduced intensity | 15 | 78.9 |
| Donor type | ||
| 8/8 matched unrelated donor | 10 | 52.6 |
| 7/8 matched unrelated donor | 1 | 5.26 |
| Matched related donor | 1 | 5.26 |
| Haploidentical | 7 | 36.8 |
| . | N . | % . |
|---|---|---|
| Total number of treated patients | 19 | |
| Median age (range) | 63 (31, 79) | |
| Gender | ||
| Male | 12 | 63.2 |
| Female | 7 | 36.8 |
| Disease | ||
| AML | 17 | 89.5 |
| De novo (% of AML) | 8 | 47.1 |
| AML-MRC (% of AML) | 7 | 36.8 |
| AML with antecedent MPN (% of AML) | 2 | 10.5 |
| MDS-EB | 2 | 10.5 |
| Cytogenetic risk | ||
| AML | ||
| Intermediate (% of AML) | 14 | 82.4 |
| Normal (% of AML) | 11 | 64.7 |
| Adverse (% of AML) | 3 | 17.6 |
| MDS | ||
| Intermediate (% of MDS) | 2 | 100 |
| IDH2 mutation subtype | ||
| R140Q | 10 | 52.6 |
| R172K | 7 | 36.8 |
| R172G | 1 | 5.26 |
| Not available | 1 | 5.26 |
| Number of lines of treatment before HCT | ||
| 1 (newly diagnosed) | 15 | 78.9 |
| 2 (R/R) | 4 | 21.1 |
| Enasidenib before HCT | 10 | 52.6 |
| Conditioning | ||
| Myeloablative | 4 | 21.1 |
| Reduced intensity | 15 | 78.9 |
| Donor type | ||
| 8/8 matched unrelated donor | 10 | 52.6 |
| 7/8 matched unrelated donor | 1 | 5.26 |
| Matched related donor | 1 | 5.26 |
| Haploidentical | 7 | 36.8 |
AML-MRC, acute myeloid leukemia with myelodysplastic changes; MPN, myeloproliferative neoplasm; MDS-EB, myelodysplastic syndrome with excess blasts.